Yarvitan (WD) 5 mg/ml - Oral solution
Yarvitan (WD) 5 mg/ml - Oral solution
Not authorised
- Mitratapide
Product identification
Medicine name:
Yarvitan (WD) 5 mg/ml - Oral solution
Active substance:
- Mitratapide
Target species:
-
Dog
Route of administration:
-
Oral use
Product details
Active substance and strength:
-
Mitratapide5.00/milligram(s)1.00millilitre(s)
Pharmaceutical form:
-
Oral solution
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QA08AB90
Legal status of supply:
-
Medicinal product subject to medical prescription
Authorisation status:
-
Surrendered
Authorised in:
-
Austria
-
Belgium
-
Bulgaria
-
Croatia
-
Cyprus
-
Czechia
-
Denmark
-
Estonia
-
Finland
-
France
-
Germany
-
Greece
-
Hungary
-
Iceland
-
Ireland
-
Italy
-
Latvia
-
Liechtenstein
-
Lithuania
-
Luxembourg
-
Malta
-
Netherlands
-
Norway
-
Poland
-
Portugal
-
Romania
-
Slovakia
-
Slovenia
-
Spain
-
Sweden
-
United Kingdom (Northern Ireland)
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
- Janssen Pharmaceutica
Marketing authorisation date:
Manufacturing sites for batch release:
- Janssen Pharmaceutica
Responsible authority:
- European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet